|Articles|February 7, 2019
Optimapharm acquires Swiss Denothex
Advertisement
Optimapharm, an independent clinical research organization (CRO), acquired Denothex Ltd. Optimapharm operates in offices across 14 European countries. It covers markets with a total population of over 500 million people, and conducts phase I – IV clinical research across Europe with a very strong footprint in Central and Eastern Europe.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
2
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
3
Using AI and Tokenized Data to Match Patients to Protocols
4
FDA Approves UCB’s Kygevi for TK2 Deficiency Based on Multi-Study Clinical Program Demonstrating Significant Survival and Motor Gains
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
